Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2

Affiliations

• ¹ Baqiyatallah Hospital, Baqiyatallah University of Medical Sciences, Tehran, Iran.
• ² Pharmacognosy Research Laboratories and Herbal Analysis Services, University of Greenwich, Central Avenue, Chatham-Maritime, Kent ME4 4TB, United Kingdom.
• ³ E. Medea Scientific Institute, Bosisio Parini, Italy.
• ⁴ Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, Luigi Sacco University Hospital, Università degli Studi di Milano, Milan, Italy.
• ⁵ Research Centre for functional Genomics, Biomedicine, and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
• ⁶ The Research Centre for Advanced Medicine Medfuture "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Romania.
• ⁷ Department of Functional Sciences, Immunology, and Allergology, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Romania.
• ⁸ Pharmaceutical Sciences Research Centre, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
• ⁹ Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland.
• ¹⁰ Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.
• ¹¹ Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.